Beamtree delivers 10% recurring revenue growth and achieves positive operating profit in FY26
Beamtree Holdings Limited (ASX: BMT) reported total revenue of $29.2m for FY26, with 94% recurring and recurring revenue up 10%, alongside a positive operating profit of $0.4m. The AI-enabled healthcare data and clinical software provider serves hospitals and pathology laboratories.
The full-year update, dated 28 August 2026, framed FY26 as a year of strategic reset under new leadership. A wide-ranging review reshaped the product portfolio, cost base and organisational structure.
The most significant organisational change was the appointment of Gareth Pye as Chief Executive Officer, bringing enterprise software experience to the go-forward strategy.
When big ASX news breaks, our subscribers know first
FY26 financial results at a glance
The results underscored the quality of Beamtree’s revenue base, with 94% of total income recurring.
The Company also reassessed the carrying values of certain intangible assets prior to 30 June 2026, writing them down by $13.1m. This was a non-cash write-down with no cash impact as at 30 June 2026, taken to provide a more accurate carrying value and a more normal depreciation and amortisation charge going forward, more reflective of ongoing investment into capitalised research and development.
Beamtree capitalised $3.7m in research and development during the year, reflecting continued product investment.
| Metric | FY26 Result | Investor Significance |
|---|---|---|
| Total revenue | $29.2m | Quality revenue base |
| Recurring revenue | 94% of total, up 10% | Predictable, sticky income |
| Operating profit | $0.4m (positive) | Disciplined cost base |
| Capitalised R&D | $3.7m | Ongoing product investment |
| Liquidity | $5.5m ($2.5m cash + $3.0m undrawn facility) | Funding flexibility |
The FY26 key financials disclosed by the Company were:
-
Total revenue of $29.2m with 94% recurring
-
Recurring revenue grew by 10%
-
Positive operating profit of $0.4m
-
Continued investment in products with $3.7m capitalised during the year
-
Liquidity of $5.5m as at 30 June 2026, comprising cash of $2.5m and an undrawn facility of $3.0m
A strategic review that reshaped the business
During the strategic review, Beamtree refined its product mix, reshaped its cost base, tightened capital allocation and sharpened its focus on sales execution. Management also strengthened the executive leadership team, simplified the organisation and clarified accountabilities across the business.
The reset was set in motion earlier in 2026 when Beamtree initiated a formal strategic review under Executive Chair Emma Gray, a process that saw all directors convert fees to equity and healthcare leader Martin Bowles join the board to strengthen governance ahead of any structural changes.
Going forward, investment is being concentrated on the products with the strongest customer resonance, margin potential and capacity for innovation.
Products in focus
The Company identified the following core products as priorities:
-
Diagnostics: Rippledown, described as market leading
-
Coding solutions: PICQ, PICQ Audit and RISQ
-
Analytics platform
Two new products were launched this year with selected customers: Autonomous Coding Solutions (ACS) and Autonomous Data Entry (ADE).
Products being exited
Beamtree determined to exit the following, each of which sat at a distance from its core hospital customer base:
-
Ability Roundtable
-
Wellness Roundtable
The Company is also winding down the Ainsoff Deterioration Index, a process being managed in careful consultation with affected customers. These changes are intended to free human and capital resources for higher-potential products.
New CEO Gareth Pye takes the helm
The appointment of Gareth Pye as Chief Executive Officer was described as the most important organisational change of the year. Pye joined after 18 years at TechnologyOne, where he helped scale an ASX-listed enterprise software business from its domestic base into one with a substantial overseas footprint.
His background spans roles as a CFO, a strategy lead and a product lead. This combination brings enterprise software go-to-market experience, product scaling capability and investor engagement to the task of commercialising Beamtree’s strategy at pace.
Pye’s appointment and compensation structure were disclosed in June 2026, with a total package of up to $950,000 spanning fixed salary, a short-term incentive, sign-on shares, and an FY27 long-term incentive, all tied directly to Board-agreed KPIs and shareholder value creation.
Gareth Pye, Chief Executive Officer
“I am excited to join Beamtree at this inflection point as we focus on our core strengths and competitive advantages Combined with our customer focus I believe that Beamtree is well positioned to achieve sustainable growth.”
Understanding AI-enabled healthcare data platforms
Beamtree applies clinical, coding and data expertise combined with AI to help hospitals and pathology laboratories improve clinical quality, coding accuracy and reimbursement outcomes. In simple terms, the technology helps healthcare providers record patient information more accurately and get paid correctly for the services they deliver.
The Company’s proprietary platforms are co-developed with customers and embedded in live workflows, delivering “system-level impact rather than point solutions.”
The new autonomous products aim to automate manual clinical administration tasks.
Beamtree describes its offering across four product segments: Diagnostic Technology, Clinical Decision Support, Coding Assistance and Data Quality, and Analytics and Knowledge Networks.
What FY26 sets up for investors
FY26 combined several threads that shape the go-forward position. A high-quality recurring revenue base, a positive operating profit and a more accurate carrying value following the non-cash impairment sit alongside a sharper product focus and an experienced new CEO.
The two new product launches, ACS and ADE, were introduced with selected customers and represent potential near-term growth avenues as adoption develops.
Liquidity of $5.5m as at 30 June 2026 supports the execution of the refined strategy. With the portfolio reshaped and leadership strengthened, management has positioned FY26 as an inflection point from which it aims to achieve sustainable growth.
Don’t Miss the Next Healthcare Tech Winner on the ASX
Big News Blast delivers FREE breaking ASX healthcare and tech news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already staying ahead of the market. Click the “Free Alerts” button at StockWire X to get the next market-moving announcement the moment it drops.